News & Events

Upcoming Events

Throughout the year, Balmes Transplantation participates in numerous scientific and investor events around the world. Each of these activities gives us an opportunity to showcase our approach and technology, build relationships with clinicians, surgeons and financial partners, and share and gain invaluable insights.

Below are the upcoming events where Balmes Transplantation will be represented.

 

LSX World Congress 2019
February 5-6, 2019 – London, UK
LSX World Congress

The LSX World Congress is a high-calibre, senior executive, two-day conference and partnering event providing the education, strategies, solutions and contacts that life science executives need to enable more effective investment, planning and strategic growth within their businesses.

 

24th AKI & CRRT Conference 2019
February 26 – March 1st, 2019 – San Diego, CA
201902_akicrrt

The CRRT Conference provides a comprehensive coverage of the field of Critical Care Nephrology and CRRT. It highlights the recent advances in the understanding of pathophysiology of critical illness, acute kidney injury, emerging strategies in the management of sepsis, multiorgan failure, development and use of biomarkers, technical advances in CRRT and the appropriate utilization of these techniques.

 

BIO-Europe Spring 2019
March 25-27, 2019 – Vienna, AT
201903_bioeurope spring 2019

This year’s event in Vienna will bring together the “who’s who” from the biotech, pharma and finance segments to allow delegates to meet more key decision makers in three days of partnering meetings than they could in a whole year.

 


Latest News and Press Releases

Balmes Transplantation Raises €700,000 in Seed Funding
Marseille, February 6, 2018 – Balmes Transplantation, an early stage innovative biotech company specializing in the fast development of combinations of repurposed drugs against kidney ischemia-reperfusion injury (IRI), announces today that it raised 700,000 euros in seed funding from the company’s top executives, Patrick Berna (founder and CEO) and Guillaume Demarne (CBDO), and from a group of angel investors.

Read full press release (PDF)